

Estimating COVID-19 vaccine breakthrough cases

1 **Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated**  
2 **individuals in the United States—January–April, 2021**

3

4 Kiersten J. Kugeler<sup>1\*</sup>, John Williamson<sup>1</sup>, Aaron T. Curns<sup>1</sup>, Jessica M. Healy<sup>1</sup>, Leisha D. Nolen<sup>1</sup>,  
5 Thomas A. Clark<sup>1</sup>, Stacey W. Martin<sup>1</sup>, Marc Fischer<sup>1</sup>

6

7 <sup>1</sup>CDC COVID-19 Response Team

8

9 \*Corresponding author: Kiersten J. Kugeler, [bio1@cdc.gov](mailto:bio1@cdc.gov), Centers for Disease Control and  
10 Prevention, 3156 Rampart Road, Fort Collins, Colorado, 80521

11

12 Abstract word count: 178

13 Word count: 2,241

14 Tables and figures: 2 tables, 1 figure

15

16 Running title: Estimating COVID-19 vaccine breakthrough infections

## Estimating COVID-19 vaccine breakthrough cases

### 17 **Abstract**

18 As of March 2021, three COVID-19 vaccines have been authorized by the U.S. Food and Drug  
19 Administration (FDA) for use in the United States. Each has substantial efficacy in preventing  
20 COVID-19. However, as efficacy from trials was <100% for all three vaccines, disease in  
21 vaccinated people is expected to occur. We created a spreadsheet-based tool to estimate the  
22 number of symptomatic vaccine breakthrough infections based on published vaccine efficacy  
23 (VE) data, percent of the population that has been fully vaccinated, and average number of  
24 COVID-19 cases reported per day. We estimate that approximately 51,000 symptomatic vaccine  
25 breakthrough infections (95% CI: ~48,000–55,000 cases) occurred in the United States during  
26 January–April 2021 among >77 million fully vaccinated people, reflecting <0.5% of COVID-19  
27 cases that occurred during that time. With ongoing SARS-CoV-2 transmission and increasing  
28 numbers of people vaccinated in the United States, vaccine breakthrough infections will continue  
29 to accumulate before population immunity is sufficient to interrupt transmission. Understanding  
30 expectations regarding number of vaccine breakthrough infections enables accurate public health  
31 messaging to help ensure that the occurrence of such cases does not negatively affect vaccine  
32 perceptions, confidence, and uptake.

33

34

35

36

## 37 **Introduction**

38 Widespread uptake of safe and effective vaccines is critical to controlling the COVID-19  
39 pandemic. Three COVID-19 vaccines have been authorized by the U.S. Food and Drug  
40 Administration (FDA) for use in the United States, including the 2-dose Pfizer-BioNTech  
41 BNT162b2 mRNA and Moderna mRNA-1273 vaccines and the single-dose adenovirus-based  
42 Johnson & Johnson/Janssen Ad.26.COV2.S vaccine (1-3). In large, randomized controlled trials,  
43 the Pfizer-BioNTech and Moderna mRNA vaccines each had an efficacy of  $\geq 94\%$  in preventing  
44 symptomatic, laboratory-confirmed COVID-19 following the 2-dose series (4, 5). Among the  
45 over 32,000 people who received either the Pfizer-BioNTech or Moderna vaccine during those  
46 clinical trials, 20 developed COVID-19 after vaccination. Among the 19,514 people randomized  
47 to receive Janssen vaccine during those trials, 116 developed COVID-19 following vaccination,  
48 resulting in an efficacy of 67% against moderate-to-severe COVID-19 (6). The Pfizer-BioNTech  
49 and Moderna vaccines were authorized by FDA and recommended by the Advisory Committee  
50 of Immunization Practices for use in the United States in December 2020 (2, 3, 7, 8), while the  
51 Janssen vaccine was authorized and recommended for use at the end of February 2021 (1, 9).  
52 Vaccine administration in the United States began within a few days of authorization for each  
53 vaccine.

54 As no vaccine is 100% effective at preventing illness, COVID-19 occurring among  
55 vaccinated people, or symptomatic vaccine breakthrough infections, are expected. Amid  
56 increases in vaccination coverage in the setting of widespread SARS-CoV-2 transmission, the  
57 numbers of vaccine breakthrough infections could be substantial. We estimated the number of  
58 symptomatic vaccine breakthrough infections expected in the United States based on published

## Estimating COVID-19 vaccine breakthrough cases

59 vaccine efficacy (VE) data, percent of the population that had been fully vaccinated, and reported  
60 COVID-19 case counts.

61

### 62 **Methods**

63 We developed a tool in Microsoft Excel<sup>®</sup> to estimate the expected number of symptomatic  
64 vaccine breakthrough infections per day among U.S. adults (aged  $\geq 18$  years). Inputs are the 7-  
65 day moving average for daily numbers of COVID-19 cases in the United States as reported to the  
66 Centers for Disease Control and Prevention (CDC), the cumulative number of persons fully  
67 vaccinated as reported to CDC as of 14 days prior to each 7-day average case count, and VE data  
68 from phase 3 trials of the three vaccines authorized in the United States (1-3, 10, 11). The  
69 number of symptomatic vaccine breakthrough infections, rather than all symptomatic and  
70 asymptomatic vaccine breakthrough infections, were calculated because prevention of  
71 symptomatic disease was the primary phase 3 clinical trial endpoint reported for the COVID-19  
72 vaccines authorized in the United States.

73 Breakthrough cases were defined as those occurring in persons  $\geq 14$  days after completion  
74 of vaccination with an authorized COVID-19 vaccine, a delay to reflect when maximum  
75 immunity conveyed by vaccination is reached. Given the similar reported VE from clinical trials  
76 for the Pfizer-BioNTech and Moderna vaccines, the average VE of 94.6% was used for both  
77 mRNA vaccines in the calculator (4, 5), while 66.9% VE was used for the Janssen vaccine (1).  
78 Calculations were restricted to persons aged  $\geq 18$  years, the primary population that received  
79 vaccines during the study period. Because available data suggest that 88.3% of reported U.S.  
80 cases occur among persons  $\geq 18$  years of age, we similarly restricted the denominator data used  
81 for this analysis to 88.3% of the total population per 2019 U.S. census estimates (12).

Estimating COVID-19 vaccine breakthrough cases

82           The number of symptomatic vaccine breakthrough infections expected per day is a  
 83 function of VE and vaccination coverage in the population. For these calculations,  $C$  denotes the  
 84 7-day moving average for daily number of reported COVID-19 cases and  $V$  represents different  
 85 vaccination “groups” according to numeric subscripts: 0 for unvaccinated or not fully vaccinated,  
 86 1 for Janssen vaccine, and 2 for Moderna and Pfizer-BioNTech vaccines;  $\%V$  is the percent of  
 87 the population fully vaccinated in each vaccine group. VE is calculated as  $(1 - \text{the risk ratio}$   
 88  $[\text{RR}])$ , where RR is the ratio of confirmed symptomatic SARS-CoV-2 infections per 1000  
 89 person-years among those receiving vaccine in phase 3 trials divided by those receiving placebo.  
 90 The Janssen  $\text{RR}_1$  was 0.331 ( $\text{VE}_1 = 0.669$ ), the Pfizer-BioNTech and Moderna  $\text{RR}_2$  was 0.054  
 91 ( $\text{VE}_2 = 0.946$ ), while  $\text{RR}_0$  was defined as 1 ( $\text{VE}_0 = 0$ ) for people who are unvaccinated or not  
 92 fully vaccinated. The expected number of symptomatic vaccine breakthrough infections per day  
 93 is calculated as:

$$94 \quad \frac{(\widehat{\text{RR}}_1 * \%V_1) + (\widehat{\text{RR}}_2 * \%V_2)}{\%V_0 + (\widehat{\text{RR}}_1 * \%V_1) + (\widehat{\text{RR}}_2 * \%V_2)}$$

95 Variance was calculated based on available phase 3 clinical trial data for the Pfizer-BioNTech  
 96 and Moderna vaccine trials using Poisson regression models. The pooled variance of the  
 97 expected symptomatic vaccine breakthrough infections was estimated to be  $\text{Var}(\hat{\beta}_1) = 0.01149$ ,  
 98  $\text{Var}(\hat{\beta}_2) = 0.05551$ , with  $\text{Cov}(\hat{\beta}_1, \hat{\beta}_2) = 0$  and calculated as

$$99 \quad C^2 \frac{(\widehat{\text{RR}}_1 * \%V_0 * \%V_1)}{\{[\%V_0 + (\widehat{\text{RR}}_1 * \%V_1) + (\widehat{\text{RR}}_2 * \%V_2)] * 2\}^2} \text{Var}\hat{\beta}_1$$

$$100 \quad + \quad C^2 \frac{(\widehat{\text{RR}}_2 * \%V_0 * \%V_2)}{\{[\%V_0 + (\widehat{\text{RR}}_1 * \%V_1) + (\widehat{\text{RR}}_2 * \%V_2)] * 2\}^2} \text{Var}\hat{\beta}_2$$

101

## Estimating COVID-19 vaccine breakthrough cases

102           The first persons in the United States to be vaccinated against SARS-CoV-2 completed  
103 their 2-dose series during the week of January 4, 2021. Therefore, we began calculating the  
104 expected number of symptomatic vaccine breakthrough infections 14 days later, the week  
105 beginning January 17. We calculated weekly estimates using average case counts and  
106 vaccination coverage as of the Sunday beginning each week and then multiplied the daily  
107 estimate by seven. We estimated per-week symptomatic breakthrough infections through the  
108 week beginning April 25. Incorporation of Janssen vaccine into the estimates began in mid-  
109 March. We calculated cumulative expected counts to date by summing weekly expected vaccine  
110 breakthrough case counts. We derived 95% confidence intervals (CI) around cumulative counts  
111 by summing weekly variances as described above into standard CI calculations.

112           To understand the relative influence of community transmission, vaccination coverage,  
113 and VE in determining the number of expected vaccine breakthrough infections, we calculated  
114 expected cumulative counts during the same time period under three hypothetical scenarios: 1)  
115 doubling the average daily COVID-19 case counts each week; 2) doubling cumulative  
116 vaccination coverage each week; and 3) modifying population vaccination coverage during  
117 January–April such that it entirely reflected VE of 67%, VE associated with the Janssen vaccine.

118

## 119 **Results**

120 Over 11 million COVID-19 cases were reported in the United States during January–April 2021  
121 (10). The number of COVID-19 cases reported per day during this period ranged from a high of  
122 approximately 217,000 cases in January to a low of approximately 53,000 cases in March (10).  
123 The estimated number of symptomatic vaccine breakthrough infections in the United States

## Estimating COVID-19 vaccine breakthrough cases

124 ranged from a low of approximately nine per week in January to 11,300 during the last week of  
125 April (Table 1 and Figure).

126 As of the end of April, we estimate that a total of 51,425 symptomatic vaccine  
127 breakthrough infections (95% CI: 47,607–55,243 cases) occurred in the United States among  
128 >77 million fully vaccinated people (Table 1 and Figure). On average, starting in February, the  
129 number of expected vaccine breakthrough infections increased by 37% each week, becoming  
130 exponential; this trajectory slowed during the last week of April amid falling numbers of  
131 COVID-19 cases in the United States (Figure) (10). The number of expected vaccine  
132 breakthrough infections during that time translates to a cumulative incidence of approximately  
133 66 vaccine breakthrough infections per 100,000 fully vaccinated people.

134 The expected number of vaccine breakthrough infections varied substantially under  
135 different hypothetical scenarios reflective of 1) doubling daily average case counts, 2) doubling  
136 the vaccination coverage, and 3) all vaccination occurring at VE of 67% (Table 2). The  
137 relationship between COVID-19 cases and the expected number of vaccine breakthrough  
138 infections was proportional (i.e., when case counts doubled, so did symptomatic vaccine  
139 breakthrough infections). The doubling of vaccination coverage more than doubled the number  
140 of expected breakthrough cases. VE had the most influence on the expected number of  
141 symptomatic vaccine breakthrough infections. Compared to vaccination with an average VE of  
142 nearly 95%, as occurred during January through April in the United States, a hypothetical  
143 scenario in which all vaccination occurred at VE of about 67% nearly quadrupled the number of  
144 expected symptomatic vaccine breakthrough infections without modifying other parameters.

145

## 146 **Discussion**

## Estimating COVID-19 vaccine breakthrough cases

147 We created a spreadsheet-based calculator to estimate the number of symptomatic vaccine  
148 breakthrough infections in the United States based on the average number of COVID-19 cases,  
149 percent of the population fully vaccinated, and published efficacies of the three FDA-authorized  
150 vaccines. Using this tool, we estimate that approximately 51,000 symptomatic SARS-CoV-2  
151 vaccine breakthrough infections occurred among the over 77 million people fully vaccinated in  
152 the United States by the middle of April. These symptomatic breakthrough infections represent  
153 <0.5% of all COVID-19 cases that occurred during January–April 2021. Vaccine breakthrough  
154 infections occurred in only a small fraction of all vaccinated persons and comprised only a small  
155 fraction of all COVID-19 cases. Understanding the number of expected vaccine breakthrough  
156 infections is important for accurate public health messaging to help ensure that the occurrence of  
157 such cases does not negatively affect vaccine perceptions, confidence, and uptake.

158 We developed this tool incorporating ideal VE scenarios. Real-world vaccine  
159 effectiveness may be lower, particularly for people who are older or have underlying health  
160 conditions (13, 14). Lower average effectiveness also could result from decreased protection  
161 against certain SARS-CoV-2 variants. Nevertheless, early vaccine effectiveness studies in the  
162 United States and elsewhere demonstrate high effectiveness of mRNA vaccines against  
163 symptomatic infection and severe disease in various real-world situations, including amid  
164 increasing circulation of SARS-CoV-2 variants of concern (15, 16), including approximately  
165 95% effectiveness among large cohorts of healthcare workers and >85% among residents of  
166 skilled nursing facilities (17-22). While we used efficacy data from clinical trials as inputs to  
167 estimate expected vaccine breakthrough infections, these inputs could be updated using real-  
168 world vaccine effectiveness data as those become increasingly available.

## Estimating COVID-19 vaccine breakthrough cases

169 COVID-19 vaccines have demonstrated the ability to mitigate risk of severe disease,  
170 hospitalization, and death among persons infected following vaccination (4, 5, 13, 17). Clinical  
171 trial endpoints utilized here were for prevention of symptomatic infection; the effectiveness of  
172 authorized vaccines at preventing asymptomatic SARS-CoV-2 infection is still unclear but  
173 preliminary reports suggest the mRNA vaccines may be >90% effective at preventing infection  
174 (13, 14, 17, 21, 23). We did not incorporate asymptomatic infections into these calculations.

175 The analytic approach described here is based on several assumptions and limitations that  
176 affect how our results should be interpreted. First, this approach is based on reported case counts  
177 and does not account for the population at-risk, susceptibility of persons previously infected, or  
178 duration of immunity following vaccination. Second, these calculations assume that vaccinated  
179 and unvaccinated people have the same risk of exposure to SARS-CoV-2, which may not be true  
180 at the population level. Third, we define vaccine breakthrough infections as those occurring more  
181 than two weeks after completion of vaccination; these figures do not include people who may  
182 become infected following partial vaccination or prior to 14 days following completion of  
183 vaccination. Fourth, reported COVID-19 case counts stratified by patient age are not available  
184 from all states (12). Our assumption that adults comprise 88.3% of reported cases reflects  
185 cumulative trends since the beginning of the pandemic; these data may not reflect the age  
186 distribution during the weeks included here and only approximate the number of COVID-19  
187 cases occurring among adults. If the proportion of total cases occurring among adults decreased  
188 over time, our assumption would yield an overestimate of vaccine breakthrough cases. As  
189 younger age groups commence vaccination, calculations should be updated to reflect the entire  
190 population. Lastly, reporting delays among both COVID-19 case and vaccine administration data  
191 vary, and data are often updated retrospectively. Therefore, the figures used for these

## Estimating COVID-19 vaccine breakthrough cases

192 calculations should be viewed as approximations. Collectively, because of these limitations, the  
193 specific estimated counts should be interpreted with caution. Nevertheless, they provide useful  
194 context for guiding expectations.

195 Risk reduction provided by any vaccination is inherently relative, and the number of  
196 cases among vaccinated persons assuming equal exposure as unvaccinated persons is directly  
197 linked to vaccination coverage and disease incidence. Even with highly effective vaccines, given  
198 the large number of people being vaccinated in the United States and high levels of SARS-CoV-  
199 2 transmission in some parts of the country, tens of thousands of symptomatic vaccine  
200 breakthrough infections are expected. The methods described here can be used by public health  
201 officials to determine if the frequency of vaccine breakthrough infections reported in their  
202 jurisdictions are consistent with expectations based on vaccine efficacy from clinical trials.  
203 Furthermore, public health messaging regarding expected vaccine breakthrough infections is  
204 important to assure the public that this is expected, is not cause for alarm, and does not indicate  
205 that vaccines are not preventing COVID-19.

206 Vaccine breakthrough infections are expected to continue to accumulate amid ongoing  
207 widespread community transmission of SARS-CoV-2 and increasing vaccination coverage.  
208 However, the number of COVID-19 cases, hospitalizations, and deaths prevented among  
209 vaccinated persons will far exceed the numbers of vaccine breakthrough infections. CDC is  
210 working with public health officials nationwide to monitor vaccine breakthrough infections,  
211 including those that result in severe disease, and to identify unexpected trends in characteristics  
212 of people with vaccine breakthrough infections or patterns associated with infecting strains.

213

214 Acknowledgments: CDC's COVID-19 Vaccine Breakthrough Case Investigation Team.

## Estimating COVID-19 vaccine breakthrough cases

215

216 **Funding.** This work was supported by the U.S. Centers for Disease Control and Prevention.

217

218 **Disclaimers.** The findings and conclusions in this report are those of the author(s) and do not

219 necessarily represent the official position of the Centers for Disease Control and Prevention.

220 Names of specific vendors, manufacturers, or products are included for informational purposes

221 and does not imply endorsement of the vendors, manufacturers, or products by the Centers for

222 Disease Control and Prevention or the U.S Department of Health and Human Services.

223

## 224 **References**

225 1. United States Food and Drug Administration. Janssen Biotech Emergency Use

226 Authorization. 2021. Available from: <https://www.fda.gov/media/146303/download>.

227 2. United States Food and Drug Administration. Pfizer-BioNTech Emergency Use

228 Authorization. 2020. Available from: <https://www.fda.gov/media/144412/download>.

229 3. United States Food and Drug Administration. ModernaTX Emergency Use

230 Authorization. 2020. Available from: <https://www.fda.gov/media/144636/download>.

231 4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and

232 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-

233 15.10.1056/NEJMoa2034577.

234 5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and

235 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-

236 16.10.1056/NEJMoa2035389.

Estimating COVID-19 vaccine breakthrough cases

- 237 6. Janssen Biotech Inc. Vaccines and Related Biologic Products Advisory Committee  
238 Meeting, FDA Briefing Document. 2021. updated February 26, 2021. Available from:  
239 <https://www.fda.gov/media/146217/download>.
- 240 7. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The  
241 Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-  
242 BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly  
243 Rep. 2020;69(50):1922-4.10.15585/mmwr.mm6950e2.
- 244 8. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The  
245 Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna  
246 COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep.  
247 2021;69(5152):1653-6.10.15585/mmwr.mm695152e1.
- 248 9. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory  
249 Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19  
250 Vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):329-  
251 32.10.15585/mmwr.mm7009e4.
- 252 10. Centers for Disease Control and Prevention. CDC COVID Data Tracker, Trends in  
253 Number of COVID-19 Cases and Deaths in the US Reported to CDC. 2021. Available from:  
254 [https://covid.cdc.gov/covid-data-tracker/#trends\\_dailytrendscases](https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases).
- 255 11. Centers for Disease Control and Prevention. CDC COVID Data Tracker, Trends in  
256 Number of COVID-19 Vaccinations in the US. 2021. Available from:  
257 <https://covid.cdc.gov/covid-data-tracker/#vaccination-trends>.

Estimating COVID-19 vaccine breakthrough cases

- 258 12. Centers for Disease Control and Prevention. CDC COVID Data Tracker, COVID-19  
259 Weekly Cases and Deaths per 100,000 Population by Age, Race/Ethnicity, and Sex. 2021.  
260 Available from: <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>.
- 261 13. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA  
262 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med.  
263 2021;384(15):1412-23.10.1056/NEJMoa2101765.
- 264 14. Britton A, Jacobs Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, et al.  
265 Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled  
266 Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February  
267 2021. MMWR Morb Mortal Wkly Rep. 2021;70(11):396-401.10.15585/mmwr.mm7011e3.
- 268 15. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and  
269 Definitions. 2021. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)  
270 [updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html).
- 271 16. Centers for Disease Control and Prevention. CDC COVID Data Tracker, Variant  
272 Proportions. 2021. Available from: [https://covid.cdc.gov/covid-data-tracker/#variant-](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)  
273 [proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
- 274 17. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim  
275 Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in  
276 Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other  
277 Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR  
278 Morb Mortal Wkly Rep. 2021;70(13):495-500.10.15585/mmwr.mm7013e3.
- 279 18. Tenforde MW, Olson SM, Self WH. Effectiveness of Pfizer-BioNTech and Moderna  
280 Vaccines Against COVID-19 Among Hospitalized Adults Aged  $\geq 65$  Years — United States,

Estimating COVID-19 vaccine breakthrough cases

- 281 January–March 2021. MMWR Morb Mortal Wkly Rep. 2021;epub: 28 April  
282 2021.<http://dx.doi.org/10.15585/mmwr.mm7018e1>.
- 283 19. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness  
284 of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare  
285 personnel. Clin Infect Dis. 2021.10.1093/cid/ciab361.
- 286 20. Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, et al. COVID-19  
287 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility  
288 After Vaccination Program - Kentucky, March 2021. MMWR Morb Mortal Wkly Rep.  
289 2021;70(17):639-43.10.15585/mmwr.mm7017e2.
- 290 21. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and  
291 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19  
292 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an  
293 observational study using national surveillance data. Lancet. 2021.10.1016/S0140-  
294 6736(21)00947-8.
- 295 22. Pilishvili T, Fleming-Dutra KE, Farrar JL ea. Interim Estimates of Vaccine Effectiveness  
296 of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33  
297 U.S. Sites, January–March 2021 MMWR Morb Mortal Wkly Rep. 2021;ePub: 14 May 2021  
298 <http://dx.doi.org/10.15585/mmwr.mm7020e2>.
- 299 23. Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the  
300 COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural  
301 COVID-19 Molecular Screening. Clin Infect Dis. 2021.10.1093/cid/ciab229.

302

303

**Table 1. COVID-19 case counts, vaccine coverage, and expected number of symptomatic vaccine breakthrough infections among adults (aged ≥18 years), by week — United States, January–April 2021**

Week start date	Average daily COVID-19 case counts	Full vaccination coverage as of 2 weeks prior*	Estimated number of expected symptomatic vaccine breakthrough infections			
			Per week	(95% CI)	Cumulative	(95% CI)
Jan 17	191,532	0.01%	9	(7–10)	–	
Jan 24	148,605	0.44%	251	(198–303)	259	(206–312)
Jan 31	127,743	0.93%	452	(357–547)	711	(602–819)
Feb 7	102,923	1.57%	619	(489–749)	1,330	(1,161–1,500)
Feb 14	78,636	2.73%	834	(659–1,008)	2,164	(1,920–2,407)
Feb 21	56,260	4.42%	981	(775–1,186)	3,144	(2,826–3,463)
Feb 28	58,961	6.54%	1,553	(1,228–1,878)	4,697	(4,242–5,152)
Mar 7	50,674	8.55%	1,781	(1,409–2,153)	6,478	(5,890–7,066)
Mar 14	46,574	11.08%	2,180	(1,725–2,635)	8,658	(7,915–9,402)
Mar 21	47,269	13.52% <sup>†</sup>	2,769	(2,192–3,346)	11,428	(10,487–12,369)
Mar 28	54,386	16.33% <sup>†</sup>	4,541	(3,681–5,400)	15,968	(14,694–17,243)

Estimating COVID-19 vaccine breakthrough cases

Apr 4	56,061	18.79% <sup>†</sup>	6,008	(4,861–7,115)	21,977	(20,262–23,691)
Apr 11	60,564	21.92% <sup>†</sup>	8,079	(6,520–9,638)	30,056	(27,739–32,373)
Apr 18	60,639	25.70% <sup>†</sup>	10,051	(8,106–11,997)	40,107	(37,081–43,133)
Apr 25	49,542	30.52% <sup>†</sup>	11,318	(8,989–13,646)	51,425	(47,607–55,243)

CI=Confidence intervals

\*Proportion of the adult population fully vaccinated (completion of an FDA-authorized vaccine or vaccine series) as of 14 days prior to date noted

<sup>†</sup>0.5%-2.5% vaccinated with the Janssen vaccine

304  
305  
306  
307  
308  
309  
310  
311  
312

**Table 2. Expected cumulative number of symptomatic COVID-19 vaccine breakthrough infections under differing hypothetical scenarios of disease incidence, vaccination coverage, and vaccine efficacy—United States, January–April 2021**

Scenario	Estimated cumulative number of symptomatic breakthrough infections (95% CI)	Percent change from baseline
Baseline*	51,425 (47,607–55,243)	–
Scenario 1: Case counts doubled each week from baseline	102,850 (95,214–110,86)	100%
Scenario 2: Vaccination coverage doubled each week from baseline	139,735 (129,132–150,338)	172%
Scenario 3: Population vaccination coverage entirely with a vaccine with 67% VE)	235,102 (200,968–269,237)	357%


CI=Confidence intervals; VE=Vaccine efficacy

\*Estimated cumulative number of expected symptomatic vaccine breakthrough cases as of the week beginning April 25, 2021

313

314

315 **Figure. Estimated symptomatic COVID-19 vaccine breakthrough infections per week and cumulatively in the United States**  
316 **from January–April 2021**



317  
318  
319